Abeona announces pricing of public offering of common stock and pre‑funded warrants

New york and cleveland, dec. 20, 2019 (globe newswire) --  abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in gene and cell therapy, today announced the pricing of its public offering of 26,982,945 shares of its common stock at a public offering price of $2.50 per share and in lieu of common stock, pre-funded warrants to purchase 9,017,055 shares of its common stock at a purchase price of $2.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. the aggregate gross proceeds from the offering are expected to be $90 million, before deducting the underwriting discounts and commissions and other offering expenses payable by abeona. all of the shares of common stock and pre-funded warrants are being offered by abeona. in addition, abeona has granted the underwriters a 30-day option to purchase up to an additional 5,400,000 shares of its common stock from abeona at the public offering price, less the underwriting discounts and commissions. the offering is expected to close on december 24, 2019, subject to the satisfaction of customary closing conditions.
ABEO Ratings Summary
ABEO Quant Ranking